S. Nagao

Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor

D. Ito, K. Sawada, K. Miyazaki, 2011, International journal of molecular medicine.

Transforming growth factor-beta1 stimulates contraction of human glioblastoma cell-mediated collagen lattice through enhanced alpha2 integrin expression.

M. Nakanishi, M. Hasegawa, K. Miyake, 2000, Journal of neuropathology and experimental neurology.

Inhibition of topoisomerase II alpha subunit de novo synthesis by specific antisense oligonucleotides suppresses human glioma T98G cell growth.

S. Kimura, S. Nagao, M. Shin, 1999, Neurologia medico-chirurgica.

Discovery of a potent and selective Axl inhibitor in preclinical model.

D. Ito, T. Nakagawa, T. Matsushima, 2021, Bioorganic & medicinal chemistry.

Synthesis and structure-activity relationships of novel, potent, orally active hypoxia-inducible factor-1 inhibitors.

D. Ito, K. Miyazaki, K. Okamoto, 2014, Bioorganic & medicinal chemistry.

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models

T. Nakagawa, Yuji Yamamoto, K. Okamoto, 2016, Molecular Cancer Therapeutics.

What Does It Take to Develop Structurally Complex Molecules by Total Synthesis? Rapid Process Development and GMP Manufacturing of E7130 Drug Substance for First-in-Human Clinical Study

S. Nagao, Kenzo Yahata, Yosuke Kaburagi, 2024, Organic Process Research & Development.

Ten-Gram-Scale Total Synthesis of the Anticancer Drug Candidate E7130 to Supply Clinical Trials.

S. Nagao, Kenzo Yahata, K. Iso, 2024, Organic letters.